Category Archives: IPO

The Big Apple’s 3 Ingredient Recipe for Success

1. Keeping Commercialisation in New York. There are obvious benefits in holding on to your home-grown innovation. In New York’s case, where the ultimate aim is to foster a thriving…

Searing temperatures and hot debate at HealthEx London CEO/CFO Forum

On the hottest day on record for over 165 years, 30 CEOs and CFOs from many of the UK’s leading listed life science and healthcare companies made the journey to Westminster,…

Life science IPOs: listing in UK or US

The decision to take a company public is never taken lightly. For life science companies, however, that decision is further complicated by deciding where to list? Life science IPOs are back…

Turning the tide: attracting transatlantic biotech issuers to AIM

London Stock Exchange is a diversified international exchange Group that sits at the heart of the world’s financial community. Through its markets, the Group offers international business, and investors, unrivalled access to Europe’s…

View of an active private life science investor

In March, Jon Moulton increased his shareholding in Redx Pharma as the biotech company successfully completed it’s IPO on London’s AIM. Jon has long experience of turnarounds, having invested in…

From developing highly differentiated ‘best-in-class’ new drugs to IPO

Redx is focused on the development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer and infection. By improving the characteristics of existing drug classes…

Using conformational design to target a $9bn therapeutic market

C4X Discovery, a Manchester-based, AIM-listed Company which uses an NMR-based technique to optimise drug discovery, possess a unique drug discovery technology has the potential to cut preclinical development times and cost by…

US Life Science Listings take to AIM

For those of you not well versed in Latin, ‘Omne Trium Perfectum’ refers to the notion that everything that comes in threes is perfect or every set of three is…

May 2015 Drugs & Dealers Magazine Released

Biotech and Money are pleased to announce the release of the latest Drugs & Dealers Magazine. The May issue is the third of 6 bi-monthly publications in 2015 aimed at providing insight,…

How to achieve a successful life science exit

What follows is the final summary from the 22 April Biotechs and the City evening event, in which over 80 executives from across London, Cambridge and Oxford attended the ‘From…